

## 20<sup>th</sup> Scandinavian Meeting on Parkinson's Disease and Related Disorders

### Program committee and organisation

Aasly, Jan, Norway	<a href="mailto:jan.aasly@ntnu.no">jan.aasly@ntnu.no</a>
Bjornsdottir, Anna, Iceland	<a href="mailto:abjorns@gmail.com">abjorns@gmail.com</a>
Dietrichs, Espen, Norway	<a href="mailto:espen.dietrichs@klinmed.uio.no">espen.dietrichs@klinmed.uio.no</a>
Henriksen, Tove	<a href="mailto:Tove.Henriksen@regionh.dk">Tove.Henriksen@regionh.dk</a>
Hvid-Danielsen, Erik, Denmark	<a href="mailto:ehdanielsen@dadlnet.dk">ehdanielsen@dadlnet.dk</a>
Mardosiene, Skirmante	<a href="mailto:Skirmante.Mardosiene@regionh.dk">Skirmante.Mardosiene@regionh.dk</a>
Martikainen, Mika, Finland	<a href="mailto:mika.martikainen@tyks.fi">mika.martikainen@tyks.fi</a>
Odin, Per, Germany	<a href="mailto:per.odin@klinikum-bremerhaven.de">per.odin@klinikum-bremerhaven.de</a>
Sven Pålhagen, Sweden	<a href="mailto:sven.palhagen@gmail.com">sven.palhagen@gmail.com</a>
Sigurdadottir, Gudrun, Island	<a href="mailto:gudrun@setrid.is">gudrun@setrid.is</a>
Widner, Håkan, Sweden	<a href="mailto:hakan.widner@med.lu.se">hakan.widner@med.lu.se</a>
Wiksten, Markus, Finland	<a href="mailto:markus.wiksten@hus.fi">markus.wiksten@hus.fi</a>

**Scientific Sponsor: Scandinavian Movement Disorder Society**

**Commercial Sponsors: AbbVie, Abbott, Boston Scientific, Evolan, Global Kinetics, Medtronic, Nordic Infucare, Sensidos, Zambon**

**Organisation: Tiziana Saraceno [tiziana.saraceno@themeetingcompany.se]**

**Timepoint: 22-23 April 2022**

**Venue: Scandic St Olavs Plass, Oslo**

### Language

The official languages of the symposium will be English and Scandinavian

### Meeting Time Schedule

Friday	11.30 Lunch
	12.30-19.00 Lectures
	20.00 Dinner
Saturday	08.00-13.00 Lectures

### Lectures

Each lecture should be 20 minutes long.

## Scientific Program

### Friday 22. April

**11.30-12.25 Lunch and registration**

**12.25-12.30 Opening of the meeting**

**12.30-14.30 Pathogenesis**

**Where does PD start?**

Per Borghammer, Denmark

**Neurogenetics of PD: Update and clinical relevance**

Thomas Gasser, Germany

**The role of inflammation in Parkinson's disease**

Vidar Gundersen, Norway

**Translational approaches to treatment of Parkinson's disease**

Mathias Toft, Norway

**Symptomatology**

**14.30-15.00 Motor**

**Postural disorders in Parkinson's Disease**

Nils Margraf, Germany

**15.00-15.30 Coffee**

**15.30-16.00 Non-motor**

**Comparing and contrasting the motor and non-motor effects of advanced therapies in PD**

Ray Chaudhuri, England

**16.00-17.30 Therapy of advanced PD**

**Placebo effects in PD**

Joaquim Ferreira, Portugal

**DBS: Latest developments**

Elena Moro, France

**DBS: Best target for DBS in Tremor**

Inger Marie Skogseid, Norway

**17.30-17.45 Coffee**

**17.45-18.45 Best papers**

**Best 3 experimental papers 2019-20**

Anders Björklund, Sweden

**Best 3 clinical papers 2019-20**

Andrew Lees, England

**18.45-19.15 Pro-Cons Session**

**Shall we start PD therapy with L-dopa?**

**Yes:** Espen Dietrichs

**No:** Christian Oehlwein

## **Saturday 23. April**

### **08.00-10.00 Therapy of advanced PD. Kognition**

#### **Wearables for monitoring PD and its treatments**

Filip Bergqvist, Sweden

#### **Pump-based therapies for PD: state of the art**

Tove Henriksen, Denmark

#### **Differential Indication for Advanced therapies**

Werner Poewe, Austria

#### **Cognitive decline in PD: Clinical phenotype, imaging and treatment strategies**

Irene Rektorova, Czech Republic

### **10.00-10.30 Coffee**

### **10.30-11.30 Future treatment**

#### **Trophic factor-based therapy: GDNF**

Alan Whone, England

#### **Trophic Factors in Parkinson's disease: CDNF**

Per Svenningsson, Sweden

### **11.30-13.30 Non-PD Movement Disorders**

#### **MSA: Clinical manifestations and therapeutic options**

Gregor Wenning, Austria

#### **PSP: Clinical manifestations and therapeutic options**

Gunther Höglinger, Germany

#### **Therapeutic options for Dystonia**

Marie Vidailhet, France

#### **Tics and Tourette: Symptomatology and Clinical Management**

Kirsten Muller-Vahl, Germany